Home » Novartis Says Acromegaly Drug Met Primary Goal in Late-Stage Study
Novartis Says Acromegaly Drug Met Primary Goal in Late-Stage Study
Novartis said results from a late-stage study showed its novel therapy pasireotide long-acting release to be more effective than the current standard medical therapy in patients with acromegaly — a rare hormonal disorder. The study met its primary endpoint.
RTT News
RTT News
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May